Updates are available Correction dated 2017-12-12
Click to view Correction: https://doi.org/10.1007/s10120-017-0784-8
-
Authors
Kimura, Yutaka
Fujii, Masashi
Masuishi, Toshiki
Nishikawa, Kazuhiro
Kunisaki, Chikara
Matsusaka, Satoshi
Segawa, Yoshihiko
Nakamura, Masato
Sasaki, Kinro
Nagao, Narutoshi
Hatachi, Yukimasa
Yuasa, Yasuhiro
Asami, Shinya
Takeuchi, Masahiro
Furukawa, Hiroshi
Nakajima, Toshifusa
Kawase, Tomono
Kawabata, Ryohei
Kimura, Yutaka
Etou, Tetsuya
Masuishi, Toshiki
Makino, Hirochika
Ono, Hidetaka
Izumisawa, Yusuke
Kunisaki, Chikara
Nishikawa, Kazuhiro
Kawada, Junji
Matsusaka, Satoshi
Shimada, Ken
Sunakawa, Yu
Segawa, Yoshihiko
Nakamura, Masato
Satomura, Hitoshi
Sasaki, Kinro
Nagao, Narutoshi
Kunieda, Katsuyuki
Tsuji, Akihito
Satake, Hironaga
Hatachi, Yukimasa
Ishikura, Hisashi
Yuasa, Yasuhiro
Okitsu, Hiroshi
Asami, Shinya
Ito, Takahiro
Moriichi, Kentaro
Takahashi, Masazumi
Takinishi, Yasutaka
Sekikawa, Takashi
Okumura, Naoki
Ueyama, Shigemitsu
Yamamura, Noriyuki
Manaka, Dai
Oouchi, Sachiko
Ohashi, Ryuichiro
Mannami, Tomohiko
Tanabe, Kazuaki
Shiraishi, Takeshi
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000007368 at UMIN JapanDocuments that mention this clinical trial
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
https://doi.org/10.1007/s10120-017-0766-x
- License Information
-
More Information
Article History
Received: 30 June 2017
Accepted: 8 September 2017
First Online: 21 September 2017
Change Date: 12 December 2017
Change Type: Correction
Change Details: The correct name of the twelfth author should be ‘‘Yasuhiro Yuasa”, and not ‘‘Yasuhiko Yuasa’’ as given in the original publication of the article.
Compliance with ethical standards
:
: This work was supported by the Japan Clinical Cancer Research Organization (JACCRO GC-06) with funding from Taiho Pharmaceutical Co., Ltd, Japan, under a research contract (no grant number).
: Yutaka Kimura: none declared. Masashi Fujii: none declared. Toshiki Masuishi received honoraria from Taiho Pharmaceutical and Chugai Pharma. Kazuhiro Nishikawa received honoraria from Taiho Pharmaceutical, Chugai Pharma, Yakult Honsha, and Ajinomoto. Chikara Kunisaki received donations from Yakult Honsha and Chugai Pharma. Yoshihiko Segawa received speakers bureau payments from Taiho Pharmaceutical, Eisai, Novartis, and Mochida Pharmaceutical as well as research funding from Taiho Pharmaceutical, Bayer Yakuhin, PAREXEL International, GlaxoSmithKline K.K., Daiichi Sankyo, and AstraZeneca. Japan. Masato Nakamura received honoraria from Merck Serono, Taiho Pharmaceutical, and Yakult Honsha. Kinro Sasaki: none declared. Narutoshi Nagao: none declared. Yukimasa Hatachi: none declared. Yasuhiro Yuasa: none declared. Shinya Asami: none declared. Masahiro Takeuchi received honoraria from Mitsubishi Tanabe Pharma and consulting fees from Hisamitsu Pharmaceutical, Kowa, Taiho Pharmaceutical, Shionogi Pharma, Abbvie, AstraZeneca Japan, and EA Pharma. Hiroshi Furukawa: none declared. Toshifusa Nakajima: none declared.
